T. Rowe Price Group

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Lambda is a deep-learning infrastructure company that specializes in providing computation resources to enhance human progress. It offers a cloud computing platform tailored for large-scale artificial intelligence training and inference, with a focus on simplifying the deployment of deep learning models. The company's product lineup includes pre-configured servers and workstations equipped with popular machine learning frameworks, allowing clients to efficiently train complex models for various applications, such as natural language processing and drug discovery. Lambda enables AI engineers to securely and cost-effectively develop, test, and deploy AI products at scale, with solutions ranging from on-premises GPU hardware to cloud-hosted GPUs.

Lilac Solutions, Inc. is a mining technology company focused on lithium extraction, providing innovative technology and services to lithium producers. The company specializes in ion exchange beads and continuous brine processing systems, which enable the efficient production of high-purity lithium solutions from various brine resources. This technology, grounded in ion-exchange theory, allows lithium producers to enhance project development, improve lithium recovery rates, and optimize operational efficiency while also minimizing costs and environmental impact. Lilac Solutions serves industries such as electric vehicles and renewable energy storage. Incorporated in 2015, the company is headquartered in Oakland, California.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

YuLife is a London-based insurance company founded in 2016 that focuses on promoting well-being through its innovative insurance platform. By integrating gamification and behavioral science, YuLife offers life and medical insurance plans that incentivize healthy living. Users are encouraged to engage in activities such as walking and meditation, earning rewards like air miles, vouchers, and gift cards as they pursue a healthier lifestyle. This approach not only supports individual wellness but also helps businesses ensure their employees are insured while fostering a culture of health and motivation. YuLife aims to transform financial products into a force for good, making everyday wellness accessible to all.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Epirus, Inc. is a company focused on developing advanced defense technologies that utilize artificial intelligence and directed energy systems. Based in Hawthorne, California, it specializes in solid-state, software-defined high-power microwave systems designed to counter unmanned aircraft and other asymmetric threats. The company's flagship product, ELECTROMAGNETIC PULSE, functions as a drone countermeasure by delivering multiple beams simultaneously, effectively disrupting and neutralizing aerial threats. Additionally, Epirus employs AI and computer vision to enhance its capabilities in detecting and tracking various targets of interest. Founded in 2018, Epirus aims to provide innovative solutions for both national security and commercial applications, optimizing power management and efficiency in electronic warfare scenarios.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Redwood Materials, Inc. specializes in the development of innovative recycling processes aimed at creating circular supply chains for lithium-ion batteries and other electronic products. Founded by JB Straubel and based in Carson City, Nevada, the company focuses on recovering valuable materials such as lithium, nickel, copper, cobalt, and other metals from end-of-life batteries and electronics. Redwood receives approximately 10 GWh of batteries annually for recycling, which are refined and remanufactured into essential anode and cathode materials. The company is actively working to scale its production capacity to 100 GWh annually by 2025, sufficient to produce over one million electric vehicles each year. By emphasizing sustainable practices, Redwood Materials aims to reduce the environmental impact of battery production and support the growth of the electric vehicle and renewable energy storage markets.

Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

Jetti Resources is a company based in Vancouver, Canada, that specializes in developing hydrometallurgical technology for the extraction of metals from mineral ores. Founded in 2014, Jetti focuses primarily on extracting copper from low-grade primary sulfides, including chalcopyrite, which is the most abundant copper mineral ore. The company has developed a proprietary catalytic technology that enhances copper recovery from vast quantities of ore, addressing significant challenges in mineral processing. This technology integrates with existing heap leaching methods and downstream operations, allowing industrial clients to improve copper yields in a cost-effective and environmentally sustainable manner. Additionally, Jetti's technology is applicable for the extraction of zinc and nickel from sulfide ores, further diversifying its capabilities in mineral processing.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Flexe, Inc. operates a cloud-based marketplace that connects organizations seeking additional warehousing and fulfillment services with those that have surplus capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics solutions, including eCommerce fulfillment, retail distribution, and same-day delivery. Flexe's platform addresses the challenges of inventory overflow and fulfillment needs by creating an open logistics network, allowing clients such as retailers, wholesalers, manufacturers, and logistics companies to optimize their distribution capabilities. By integrating technology and flexible economic models, Flexe enables its customers to enhance their operational efficiency and respond swiftly to market demands.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Nuro, Inc. is a technology company established in 2016 and headquartered in Mountain View, California. The company specializes in manufacturing self-driving vehicles specifically designed for local goods transportation. Nuro's autonomous delivery service enhances local commerce by enabling merchants to efficiently deliver a wide range of products, including food and pharmaceuticals, directly to customers. Their fleet of electric, fully autonomous vehicles aims to provide quick, affordable, and safe delivery options, thereby transforming the logistics of local deliveries.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

Alignment Health is a healthcare organization focused on providing tailored care solutions for seniors, primarily through Medicare Advantage plans. By offering a consumer-centric platform, it allows seniors to choose their healthcare coverage and services annually. The company emphasizes a combination of technology and clinical coordination to enhance health outcomes, facilitating care through various channels, including phone, online, and in-person settings. Additionally, Alignment Health supports its partners and patients with risk management and customized services, ensuring a comprehensive approach to healthcare delivery.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Allbirds, Inc. is a San Francisco-based company founded in 2015 that specializes in manufacturing eco-friendly footwear and apparel. The company offers a variety of products, including wool runners, tree runners, and loungers for men, women, and children, as well as insoles. Allbirds focuses on using premium natural materials to create sustainable footwear designed for everyday life. The brand is committed to blending comfort, good design, and sustainability, aiming to shift the shoe industry towards a more thoughtful approach. Its products are sold through both physical retail locations and online platforms, with the majority of sales generated in the United States.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods, ranging from single pallets to full truckloads. The company offers a mobile application that features real-time shipment tracking, status updates, and ensures on-time deliveries. Founded in 2015 and based in Seattle, Washington, Convoy aims to enhance efficiency in the trucking industry, which is valued at $800 billion and is responsible for significant carbon emissions from empty trucks. By utilizing technology and data, Convoy addresses issues of waste and inefficiency, ultimately saving money for shippers, increasing earnings for drivers, and reducing carbon waste. The platform facilitates instant quotations, online bookings, automated loading suggestions, and online payments, all of which contribute to improved operational efficiency and cost reduction for clients.

Gusto is a software-as-a-service (SaaS) company focused on Human Capital Management (HCM). It offers a comprehensive, cloud-based platform that provides a range of HR and payroll services designed for small businesses. Key features of Gusto’s platform include payroll processing, benefits administration, time and attendance tracking, and employee onboarding. Additionally, it supports the management of employee benefits such as health, dental, and vision insurance. By streamlining these essential functions, Gusto aims to simplify the complexities of human resource management, enabling businesses to effectively meet their employees' needs.

Framebridge is a custom framing startup that provides an online custom framing service. The company has tackled the painful, inconvenient and costly process of custom framing an item, replacing it with an experience that places the customer first. Through a tech-forward experience and an obsessive focus on quality and materials, they have introduced a new generation of customers to the tradition of custom manufacturing. Framebridge customers can choose from a curated selection of on-trend frame styles, then upload their photos to the Framebridge website, or ship their items directly to Framebridge in prepaid packaging. The expert team at Framebridge will receive their items and handcraft beautiful custom frames to each customer's exact specifications. The finished pieces ship directly to consumers, arriving in days, ready to hang. Framebridge's transparent pricing, which is determined by the size of each item, begins at $39 and includes free shipping. Framebridge launched in 2014 as a solution to founder Susan Tynan’s ongoing frustration over getting her travel art custom framed. Framebridge investors include New Enterprise Associates (NEA), Revolution Ventures, and SWaN & Legend Venture Partners, as well as seasoned retail and technology executives with industry experience at Crate & Barrel, Rent the Runway, and LivingSocial. The company is headquartered in Washington, DC and operates manufacturing facilities in Richmond, KY, and Lanham, MD.

Checkr, Inc. is a technology company specializing in the background check industry. Founded in 2014 and headquartered in San Francisco, California, Checkr offers a range of screening services, including criminal record checks, driving checks, and identity verification. The company utilizes advanced technology, including artificial intelligence and machine learning, to deliver faster and more efficient background checks compared to traditional providers. Its platform not only enhances hiring transparency and fairness but also assists businesses in complying with regulations and improving operational efficiency. Checkr serves various sectors, including financial services, healthcare, retail, and technology, providing solutions that cater to the evolving needs of the workforce.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Wheels Up is a membership-based private aviation company in the United States that aims to make private flying more accessible and affordable. It provides on-demand private aviation services through an innovative platform that connects consumers with safety-vetted aircraft. Members can book flights, manage their accounts, and explore ride-share options using a mobile app. Wheels Up offers a variety of travel alternatives through a combination of programmatic and charter services, utilizing both owned and leased aircraft as part of an asset-light model. Additionally, members can participate in the Wheels Down program, enhancing their overall experience. The company is dedicated to delivering flexibility, service, and safety in private aviation.

Evolve is a hospitality company with a mission to make renting a vacation home easy for both guests and homeowners. They help guests rest easy knowing our homes are verified, our support is 24/7, and if their stay doesn’t meet our standards, we’ll make it right. We also make vacation rental stress-free for homeowners, partnering with them to book more and keep more of what they earn thanks to our industry-low 10% management fee.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

OfferUp, Inc. is an online platform that facilitates the buying and selling of various items within local communities. Founded in 2011 and headquartered in Bellevue, Washington, the platform allows users to post items for sale and browse new local postings using mobile devices. It caters to a wide range of product categories, including electronics, furniture, vehicles, and various household items. Users can communicate with potential buyers and sellers through messaging features, enabling them to negotiate prices and arrange meetings. OfferUp aims to create a convenient marketplace that connects people with similar interests and fosters local commerce.

Magic Leap is an augmented reality company based in the United States that specializes in developing innovative hardware and software to enhance user interaction with digital devices. Its proprietary wearable technology allows users to experience augmented reality in a visually immersive manner. By leveraging dynamic-image computing and stereoscopic 3D technology, Magic Leap creates lifelike images that blend seamlessly into the real world, enhancing the way users visualize data and access digital content. The company's approach aims to bridge the gap between digital and physical experiences, enabling a unique and engaging interaction with technology through its advanced visual output capabilities.

Audentes Therapeutics, a clinical-stage biotechnology company based in San Francisco, is dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapies, including AT132 and AT342, which are in Phase I/II clinical studies for treating X-linked myotubular myopathy and Crigler-Najjar syndrome, respectively. Additionally, it is exploring treatments for Pompe disease and catecholaminergic polymorphic ventricular tachycardia, along with vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Audentes has established collaborative agreements for research and development with Genethon and the University of Pennsylvania. Founded in 2012, Audentes Therapeutics became a subsidiary of Astellas US Holding in 2020 and operates as Astellas Gene Therapies, focusing on leveraging its expertise in gene therapy research and commercialization.

OfferUp, Inc. is an online platform that facilitates the buying and selling of various items within local communities. Founded in 2011 and headquartered in Bellevue, Washington, the platform allows users to post items for sale and browse new local postings using mobile devices. It caters to a wide range of product categories, including electronics, furniture, vehicles, and various household items. Users can communicate with potential buyers and sellers through messaging features, enabling them to negotiate prices and arrange meetings. OfferUp aims to create a convenient marketplace that connects people with similar interests and fosters local commerce.

Doximity is a digital platform designed for medical professionals in the United States, serving over 70% of physicians across various specialties and practice areas. The platform offers a range of tools that facilitate collaboration and communication among healthcare providers, allowing them to securely coordinate patient care and conduct virtual visits. Additionally, Doximity helps its members stay informed with the latest medical news and research while providing resources for career management. The company's mission focuses on enhancing the productivity of doctors to ultimately improve healthcare delivery for patients.

Domo, Inc. operates a cloud-based platform that connects all levels of an organization, from executives to frontline employees, facilitating access to real-time data and insights. Founded in 2010 and headquartered in American Fork, Utah, Domo enables users to manage their business operations via smartphones. The platform is offered as a subscription-based service, allowing users to receive notifications and respond promptly, with the capability to write back to the original systems of record. In addition to its core platform, Domo provides a Programmatic Revenue Solution that integrates complex data from ad servers and sell-side platforms into user-friendly dashboards. The company's revenue primarily comes from subscriptions to its platform and related professional services.

Dropbox is a prominent provider of secure file sharing, collaboration, and storage solutions, catering primarily to individuals and small to medium-sized businesses. Founded in 2007, Dropbox was a pioneer in the cloud storage sector and is known for its innovative approach to cross-platform file syncing. The company aims to enhance productivity by creating a more efficient work environment, focusing on unleashing creative potential. In recent years, Dropbox has diversified its offerings to include a wider array of content collaboration tools, moving beyond its original cloud storage focus to better meet the evolving needs of its users.

Peixeurbano is an online platform that enables users to find and book deals on restaurants, air tickets, beauty services, entertainment activities, and trade services according to their localities and preferences. The company was voted "Best International Startup of the Year" by the Crunchies Awards, the United States' top prize for Internet and technology startups. Peixeurbano was established in 2010 and is headquartered in Florianópolis, Brazil.

Zynga Inc. is a prominent developer and operator of social games, offering a diverse portfolio that includes popular titles such as FarmVille, Words With Friends, and Zynga Poker. Founded in 2007 and headquartered in San Francisco, California, Zynga's games are accessible on mobile platforms like iOS and Android, as well as on social networking sites such as Facebook and Snapchat. The company generates revenue primarily through mobile game downloads, in-game sales of virtual goods, and advertising services, with the majority of its income stemming from online gaming. Zynga's games have been downloaded over 6 billion times globally, reaching audiences in more than 175 countries. Additionally, Zynga has developed a next-generation platform for optimizing programmatic advertising, enhancing its capabilities in the mobile advertising space. As a wholly-owned subsidiary of Take-Two Interactive Software, Zynga continues to innovate and expand its presence in the interactive entertainment industry.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.